{"classes":[{"categories":[{"measurements":[{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"3.7","upperLimit":"NA","value":"14.7"},{"comment":"TTP median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"1.8","upperLimit":"NA","value":"6.4"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"8.7","value":"5.3"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"6.4","value":"3.7"},{"comment":"TTP median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG005","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"7.2","upperLimit":"17.3","value":"9.1"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"3.6","upperLimit":"NA","value":"9.0"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG008","lowerLimit":"3.7","upperLimit":"NA","value":"6.2"},{"groupId":"OG009","lowerLimit":"5.5","upperLimit":"12.0","value":"9.4"},{"groupId":"OG010","lowerLimit":"1.8","upperLimit":"3.8","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"14"},{"groupId":"OG010","value":"19"}],"units":"Participants"}],"description":"Time from first dose of study drug to the earliest documented evidence of PD. Per RECIST v1.1, PD defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. mRECIST used for pleural mesothelioma defines PD as an increase of at least 20% in the sum of the diameters of viable target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG000","title":"Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG001","title":"Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG002","title":"Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG003","title":"Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG004","title":"Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG005","title":"Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG006","title":"Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG007","title":"Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG008","title":"Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG009","title":"Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG010","title":"Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First Dose of Study Drug to PD (Up to 2.61 years)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}